Research programme: c29 peptide - UniQuest

Drug Profile

Research programme: c29 peptide - UniQuest

Alternative Names: NeuroProtex - UniQuest

Latest Information Update: 04 Aug 2016

Price : $50

At a glance

  • Originator University of Queensland
  • Developer UniQuest; University of Queensland
  • Class Peptides
  • Mechanism of Action Apoptosis inhibitors; TrkA receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Alzheimer's disease

Most Recent Events

  • 04 Aug 2016 Preclinical trials in Alzheimer's disease in Australia (unspecified route)
  • 04 Aug 2016 Research programme: c29 peptide - UniQuest is available for licensing - http://uniquest.com.au/filething/get/11835/Neuroprotex%20c29%20Peptide%20UniQuest.pdf
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top